Regeneration of the central nervous system using iPS cell-technologies

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Induced pluripotent stem (iPS) cells are pluripotent stem cells directly reprogrammed from cultured mouse fibroblast by introducing Oct3/4, Sox2, c-Myc, and Klf4. Cells obtained using this technology, which allows the ethical issues and immunological rejection associated with embryonic stem (ES) cells to be avoided, might be a clinically useful source for cell replacement therapies. We found that secondary neurospheres (SNSs) generated from various mouse iPS cell showed their neural differentiation capacity and teratoma formation after transplantation into the brain of immunodeficient NOD/SCID mice. We found that origin (source of somatic cells) of the iPS cells are the crucial determinant for the potential tumorigenicity of iPS-derived neural stem/progenitor cells and that their tumorigenicity results from the persistent presence of undifferentiated cells within the SNSs. Surprisingly, SNSs derived from c-Myc minusiPS cells generated without drug selection showed robust tumorigenesis, in spite of their potential to contribute adult chimeric mice without tumor formation. Furthermore, we examined whether the transplantation of non-tumorigenic Nanog-iPS-derived SNSs into mouse spinal cord injury (SCI) model could promote locomotor function recovery. As a result, we found that properly pre-evaluated iPS clone-derived neural stem/progenitor cells may be a promising cell source for future transplantation therapy of SCI.

Original languageEnglish
Pages (from-to)825-826
Number of pages2
JournalClinical Neurology
Volume49
Issue number11
DOIs
Publication statusPublished - 2009

Fingerprint

Induced Pluripotent Stem Cells
Regeneration
Central Nervous System
Technology
Neural Stem Cells
Transplantation
Spinal Cord Injuries
Stem Cells
Pluripotent Stem Cells
Inbred NOD Mouse
SCID Mice
Teratoma
Recovery of Function
Embryonic Stem Cells
Cell- and Tissue-Based Therapy
Ethics
Carcinogenesis
Clone Cells
Fibroblasts
Brain

Keywords

  • Embryonic stem cells (ES cells)
  • Induced pluripotent stem cells (iPS cells)
  • Neural stem cells
  • Spinal cord injury
  • Tumorigenicity

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Regeneration of the central nervous system using iPS cell-technologies. / Okano, Hideyuki.

In: Clinical Neurology, Vol. 49, No. 11, 2009, p. 825-826.

Research output: Contribution to journalArticle

@article{8074c343bffa47faab245d4d2b650e37,
title = "Regeneration of the central nervous system using iPS cell-technologies",
abstract = "Induced pluripotent stem (iPS) cells are pluripotent stem cells directly reprogrammed from cultured mouse fibroblast by introducing Oct3/4, Sox2, c-Myc, and Klf4. Cells obtained using this technology, which allows the ethical issues and immunological rejection associated with embryonic stem (ES) cells to be avoided, might be a clinically useful source for cell replacement therapies. We found that secondary neurospheres (SNSs) generated from various mouse iPS cell showed their neural differentiation capacity and teratoma formation after transplantation into the brain of immunodeficient NOD/SCID mice. We found that origin (source of somatic cells) of the iPS cells are the crucial determinant for the potential tumorigenicity of iPS-derived neural stem/progenitor cells and that their tumorigenicity results from the persistent presence of undifferentiated cells within the SNSs. Surprisingly, SNSs derived from c-Myc minusiPS cells generated without drug selection showed robust tumorigenesis, in spite of their potential to contribute adult chimeric mice without tumor formation. Furthermore, we examined whether the transplantation of non-tumorigenic Nanog-iPS-derived SNSs into mouse spinal cord injury (SCI) model could promote locomotor function recovery. As a result, we found that properly pre-evaluated iPS clone-derived neural stem/progenitor cells may be a promising cell source for future transplantation therapy of SCI.",
keywords = "Embryonic stem cells (ES cells), Induced pluripotent stem cells (iPS cells), Neural stem cells, Spinal cord injury, Tumorigenicity",
author = "Hideyuki Okano",
year = "2009",
doi = "10.5692/clinicalneurol.49.825",
language = "English",
volume = "49",
pages = "825--826",
journal = "Clinical Neurology",
issn = "0009-918X",
publisher = "Societas Neurologica Japonica",
number = "11",

}

TY - JOUR

T1 - Regeneration of the central nervous system using iPS cell-technologies

AU - Okano, Hideyuki

PY - 2009

Y1 - 2009

N2 - Induced pluripotent stem (iPS) cells are pluripotent stem cells directly reprogrammed from cultured mouse fibroblast by introducing Oct3/4, Sox2, c-Myc, and Klf4. Cells obtained using this technology, which allows the ethical issues and immunological rejection associated with embryonic stem (ES) cells to be avoided, might be a clinically useful source for cell replacement therapies. We found that secondary neurospheres (SNSs) generated from various mouse iPS cell showed their neural differentiation capacity and teratoma formation after transplantation into the brain of immunodeficient NOD/SCID mice. We found that origin (source of somatic cells) of the iPS cells are the crucial determinant for the potential tumorigenicity of iPS-derived neural stem/progenitor cells and that their tumorigenicity results from the persistent presence of undifferentiated cells within the SNSs. Surprisingly, SNSs derived from c-Myc minusiPS cells generated without drug selection showed robust tumorigenesis, in spite of their potential to contribute adult chimeric mice without tumor formation. Furthermore, we examined whether the transplantation of non-tumorigenic Nanog-iPS-derived SNSs into mouse spinal cord injury (SCI) model could promote locomotor function recovery. As a result, we found that properly pre-evaluated iPS clone-derived neural stem/progenitor cells may be a promising cell source for future transplantation therapy of SCI.

AB - Induced pluripotent stem (iPS) cells are pluripotent stem cells directly reprogrammed from cultured mouse fibroblast by introducing Oct3/4, Sox2, c-Myc, and Klf4. Cells obtained using this technology, which allows the ethical issues and immunological rejection associated with embryonic stem (ES) cells to be avoided, might be a clinically useful source for cell replacement therapies. We found that secondary neurospheres (SNSs) generated from various mouse iPS cell showed their neural differentiation capacity and teratoma formation after transplantation into the brain of immunodeficient NOD/SCID mice. We found that origin (source of somatic cells) of the iPS cells are the crucial determinant for the potential tumorigenicity of iPS-derived neural stem/progenitor cells and that their tumorigenicity results from the persistent presence of undifferentiated cells within the SNSs. Surprisingly, SNSs derived from c-Myc minusiPS cells generated without drug selection showed robust tumorigenesis, in spite of their potential to contribute adult chimeric mice without tumor formation. Furthermore, we examined whether the transplantation of non-tumorigenic Nanog-iPS-derived SNSs into mouse spinal cord injury (SCI) model could promote locomotor function recovery. As a result, we found that properly pre-evaluated iPS clone-derived neural stem/progenitor cells may be a promising cell source for future transplantation therapy of SCI.

KW - Embryonic stem cells (ES cells)

KW - Induced pluripotent stem cells (iPS cells)

KW - Neural stem cells

KW - Spinal cord injury

KW - Tumorigenicity

UR - http://www.scopus.com/inward/record.url?scp=77956220303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956220303&partnerID=8YFLogxK

U2 - 10.5692/clinicalneurol.49.825

DO - 10.5692/clinicalneurol.49.825

M3 - Article

VL - 49

SP - 825

EP - 826

JO - Clinical Neurology

JF - Clinical Neurology

SN - 0009-918X

IS - 11

ER -